This Week in Cardiology May 23 2025 This Week in Cardiology
7 snips
May 23, 2025 Listener feedback kicks off discussions about sports disqualification linked to genetic heart disease. Exciting updates on digoxin's role in heart failure and the implications of Brugada syndrome add depth. The show dives into innovative treatments like finerenone, weighing its efficacy against traditional options. A sharp critique of trial methodologies highlights the importance of sham controls in enhancing research validity. Overall, a blend of cutting-edge research and practical insights for healthcare professionals makes for a compelling listen!
AI Snips
Chapters
Transcript
Episode notes
Shared Decision in Sports Risks
- Physicians should avoid disqualifying athletes from sports, as disqualification is a legal and organizational issue.
- Instead, provide risk information and engage in shared decision-making with athletes about participation and intensity.
Digoxin's Renewed Heart Failure Role
- The DIGIT-HF and DECISION trials are testing digitoxin and digoxin in advanced heart failure populations to clarify their benefits.
- Prior DIG trial showed hospitalizations dropped 28%, highlighting digoxin's potential beyond mortality impact.
Challenges in Brugada Prediction
- Eleven Brugada syndrome risk prediction models exist, but all assessed as high risk of bias and have variable discriminative power.
- Prediction of rare events (0.2-0.6% per year risk) is extremely challenging, urging humility and reassurance in patient discussions.